Denosumab, a human monoclonal antibody targeting RANKL, has received FDA approval for treating osteoporosis in men and postmenopausal women and minimizing bone loss associated with metastases in patients with advanced solid tumors (Cummings et al., 2009; Lacey et al., 2012). This evidence concerns the gene TNFSF11 and osteoporosis.